Edition:
India

Cymabay Therapeutics Inc (CBAY.OQ)

CBAY.OQ on NASDAQ Stock Exchange Global Select Market

12.92USD
21 Mar 2019
Change (% chg)

-- (--)
Prev Close
$12.92
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
230,196
52-wk High
$15.00
52-wk Low
$6.33

Latest Key Developments (Source: Significant Developments)

CymaBay Announces Pricing Of Public Offering Of Common Stock
Wednesday, 6 Mar 2019 

March 6 (Reuters) - Cymabay Therapeutics Inc ::CYMABAY ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK.SAYS PUBLIC OFFERING OF 8.00 MILLION COMMON SHARES PRICED AT $12.50PER SHARE.  Full Article

Cymabay Announces Proposed Public Offering Of Common Stock
Wednesday, 6 Mar 2019 

March 5 (Reuters) - Cymabay Therapeutics Inc ::CYMABAY ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.CYMABAY THERAPEUTICS INC - COMMENCED AN UNDERWRITTEN PUBLIC OFFERING OF ITS COMMON STOCK.CYMABAY THERAPEUTICS INC - ANTICIPATES USING NET PROCEEDS FROM OFFERING TO FUND ONGOING DEVELOPMENT OF SELADELPAR.  Full Article

Cymabay Therapeutics Announces Early Enrollment Of A Phase 2B Study Of Seladelpar In Patients With Nonalcoholic Steatohepatitis
Tuesday, 19 Feb 2019 

Feb 19 (Reuters) - Cymabay Therapeutics Inc ::CYMABAY THERAPEUTICS ANNOUNCES EARLY ENROLLMENT OF A PHASE 2B STUDY OF SELADELPAR IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS.CYMABAY THERAPEUTICS INC - OVER 80% OF SUBJECTS HAD BASELINE F2 OR F3 STAGE FIBROSIS.CYMABAY THERAPEUTICS INC - SUBJECTS WERE RANDOMIZED TO SELADELPAR 10 MG, 20 MG OR 50 MG OR PLACEBO.CYMABAY THERAPEUTICS INC - TOTAL OF 181 SUBJECTS ENROLLED WITH ELEVATED LIVER FAT AND BIOPSY-CONFIRMED NASH.  Full Article

Cymabay Reports Q3 Loss Per Share Of $0.34
Wednesday, 7 Nov 2018 

Nov 6 (Reuters) - Cymabay Therapeutics Inc ::CYMABAY REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q3 LOSS PER SHARE $0.34.Q3 EARNINGS PER SHARE VIEW $-0.29 -- THOMSON REUTERS I/B/E/S.HELD $198.1 MILLION IN CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES AT SEPTEMBER 30, 2018.EXISTING CASH IS EXPECTED TO FUND CURRENT OPERATING PLAN INTO 2021.  Full Article

Cymabay Announces Pricing Of Public Offering Of Common Stock
Tuesday, 30 Jan 2018 

Jan 30 (Reuters) - Cymabay Therapeutics Inc ::CYMABAY ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK.SAYS PUBLIC OFFERING OF 11.6 MILLION COMMON SHARES PRICED AT $10.80PER SHARE.  Full Article

CymaBay Announces Proposed Public Offering Of Common Stock
Tuesday, 30 Jan 2018 

Jan 29 (Reuters) - CymaBay Therapeutics Inc ::CYMABAY ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.CYMABAY THERAPEUTICS INC - ‍ANTICIPATES USING NET PROCEEDS FROM OFFERING TO FUND ONGOING DEVELOPMENT OF SELADELPAR​.  Full Article

Cymabay Therapeutics Receives $5 Mln Milestone Payment For Arhalofenate From Kowa Pharmaceuticals America
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Cymabay Therapeutics Inc ::CYMABAY THERAPEUTICS RECEIVES $5 MILLION MILESTONE PAYMENT FOR ARHALOFENATE FROM KOWA PHARMACEUTICALS AMERICA.  Full Article

CymaBay Therapeutics Files For Mixed Shelf Of Up To $200 Mln
Saturday, 30 Dec 2017 

Dec 29 (Reuters) - CymaBay Therapeutics Inc ::CYMABAY THERAPEUTICS INC FILES FOR MIXED SHELF OF UP TO $200 MILLION - SEC FILING.  Full Article

CymaBay reports Q3 loss per share $0.21
Thursday, 9 Nov 2017 

Nov 8 (Reuters) - CymaBay Therapeutics Inc ::CymaBay reports third quarter 2017 financial results and corporate updates.Q3 loss per share $0.21.Q3 earnings per share view $-0.19 -- Thomson Reuters I/B/E/S.CymaBay Therapeutics - ‍cash, cash equivalents and marketable securities totaled $102.2 million at end of Q3 of 2017, compared to $17.0 million at Dec 31, 2016​.CymaBay Therapeutics Inc - ‍existing cash expected to fund operations into 2019​.  Full Article

Cymabay Therapeutics names Sujal Shah CEO
Tuesday, 31 Oct 2017 

Oct 31 (Reuters) - Cymabay Therapeutics Inc :Cymabay announces the appointment of Sujal Shah as president and chief executive officer.Cymabay Therapeutics Inc says ‍sujal Shah has been serving as interim president and chief executive officer since March 2017​.  Full Article